UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549

                                  FORM 10-QSB

(Mark One)
(X)  QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
     ACT OF 1934

     For the quarterly period ended September 30, 2001

( )  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

     For the transition period from ______________to_____________


                       Commission File Number 000-28311


                              HEALTHBRIDGE, INC.
            ------------------------------------------------------
            (Exact Name of Registrant as specified in its charter)

                TEXAS                                 06-1538201
            -------------                            -------------
    (State or other jurisdiction of              (IRS Employer ID No.)
     incorporation or organization)

                       1818 - 1177 West Hastings Street,
                      VANCOUVER, BRITISH COLUMBIA V6E 2K3
            ------------------------------------------------------
                   (Address of principal executive offices)

                                (604) 602-1717
            ------------------------------------------------------
                          (Issuer's telephone number)


Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for
such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.
YES  X    NO _____

Number of shares outstanding of each of the issuer's classes of common stock,
as of November 9, 2001: 15,538,346.


===============================================================================
<PAGE>
                              HEALTHBRIDGE, INC.
                 FORM 10-QSB, QUARTER ENDED SEPTEMBER 30, 2001
<TABLE>
                               TABLE OF CONTENTS

<S>                                                                       <C>
PART I - FINANCIAL INFORMATION

Item 1 - Financial Statements
         Balance Sheets as of September 30, 2001 . . . . . . . . . . . . .  3
         Statements of Operations for the Three and
              Nine Months Ended September 30, 2001 and 2000  . . . . . . .  4
         Statements of Cash Flows for the Nine Months Ended
              September 30, 2001 and 2000     . . . . . . . . . . . . . .   5
         Notes to Interim Financial Statements  . . . . . . . . . . . . .   6

         All schedules are omitted because they are not applicable or
         the required information is shown in the financial statements
         or notes thereto.

Item 2 - Management's Discussion and Analysis . . . . . . . . . . . . . .   7


PART II - OTHER INFORMATION

Item 1 - Legal Proceedings  . . . . . . . . . . . . . . . . . . . . . . .   8

Item 2 - Changes in Securities  . . . . . . . . . . . . . . . . . . . . .   8

Item 3 - Defaults Upon Senior Securities  . . . . . . . . . . . . . . . .   8

Item 4 - Submission of Matters to a Vote of Security Holders  . . . . . .   8

Item 5 - Other Information  . . . . . . . . . . . . . . . . . . . . . . .   8

Item 6 - Exhibits and Reports on Form 8-K . . . . . . . . . . . . . . . .   8

         Signatures . . . . . . . . . . . . . . . . . . . . . . . . . . .   9
</TABLE>
                                    -  2 -
===============================================================================
<PAGE>
PART I
------
Item 1.  Financial Statements
-----------------------------

                              HEALTHBRIDGE, INC.
                        (A DEVELOPMENT STAGE COMPANY)
<TABLE>
                                BALANCE SHEETS
                   SEPTEMBER 30, 2001 AND DECEMBER 31, 2000

<CAPTION>
                                                 (Unaudited)
                                                    2001               2000
                                                 ----------         ----------
<S>                                              <C>                <C>
ASSETS
Current Assets
     Cash                                        $       11         $   24,623
                                                 ----------         ----------
Total Assets Cash                                $       11         $   24,623
                                                 ==========         ==========

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
     Accounts Payable                            $  341,103         $  344,321
     Notes Payable                                   12,000            187,005
     Accrued Interest                                     0              6,292
                                                 ----------         ----------
Total Current Liabilities                           353,103            537,618

Commitments and Contingencies                          -                  -

Stockholders' Equity
     Preferred Stock:  $0.0001 Par Value,
          Authorized 25,000,000;
          Issued and Outstanding, None                None               None
     Common Stock:  $0.0001 Par Value,
          Authorized 50,000,000;
          Issued and Outstanding,
          15,538,346 and 13,236,285                   1,554              1,324
     Additional Paid In Capital                   6,000,784          5,506,398
     Deficit Accumulated During the
          Development Stage                      (6,355,430)        (6,020,717)
                                                 ----------         ----------
Total Stockholders' Equity (A Deficit)             (353,092)          (512,995)
                                                 ----------         ----------

Total Liabilities and Stockholders' Equity       $       11         $   24,623
                                                 ==========         ==========

<FN>
                 See condensed notes to financial statements.
</TABLE>
                                    -  3 -
===============================================================================
<PAGE>
                              HEALTHBRIDGE, INC.
                        (A DEVELOPMENT STAGE COMPANY)
<TABLE>
                           STATEMENTS OF OPERATIONS
     FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2001 AND 2000, AND
    FOR THE PERIOD FROM INCEPTION (FEBRUARY 17, 1993) TO SEPTEMBER 30, 2001

<CAPTION>
                                                                                                From
                                                                                             Inception
                                                                                            (February 17,
                                       Three Months Ended 09/30   Nine Months Ended 09/30     1993) to
                                       ------------------------  ------------------------   September 30,
                                          2001         2000         2001         2000           2001
                                       -----------  -----------  -----------  -----------   -------------
<S>                                    <C>          <C>           <C>         <C>           <C>
Revenues                               $         0  $         0   $        0  $         0    $         0

Expenses
   General and Administrative              178,768      112,362      331,323      633,103      1,232,824
                                       -----------  -----------  -----------  -----------    -----------
Operating Loss                            (178,768)    (112,362)    (331,323)    (633,103)    (1,232,824)

Other Income (Expense)
   Interest Expense                              0            0       (3,390)      (4,955)       (24,500)
   Interest Income                               0            0            0            0          8,339
                                       -----------  -----------  -----------  -----------    -----------
Total Other Income (Expense)                     0            0       (3,390)      (4,955)       (16,161)
                                       -----------  -----------  -----------  -----------    -----------

Loss From Continuing Operations           (178,768)    (112,362)    (334,713)    (638,058)    (1,248,985)

Loss From Discontinued Operations                0            0            0            0     (2,995,849)
                                       -----------  -----------  -----------  -----------    -----------

Net Loss Before Cumulative Effect
   of Accounting Change                   (178,768)    (112,362)    (334,713)    (638,058)    (4,244,834)

Cumulative Effect of Accounting Change        -            -            -            -          (102,500)
                                       -----------  -----------  -----------  -----------    -----------

Net Loss Available to Common
   Stockholders                        $  (178,768) $  (112,362) $  (334,713) $  (638,058)   $(4,347,334)
                                       ===========  ===========  ===========  ===========    ===========

Basic Loss Per Share:                  $    (0.01)  $    (0.02)  $    (0.02)  $    (0.05)
                                       ===========  ===========  ===========  ===========

Basic Weighted Average Number of
   Common Shares Outstanding            14,753,563   12,650,618   13,896,800   12,198,396
                                       ===========  ===========  ===========  ===========

<FN>
                 See condensed notes to financial statements.
</TABLE>
                                    -  4 -
===============================================================================
<PAGE>
                              HEALTHBRIDGE, INC.
                        (A DEVELOPMENT STAGE COMPANY)
<TABLE>
                           STATEMENTS OF CASH FLOWS
     FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2001 AND 2000, AND
    FOR THE PERIOD FROM INCEPTION (FEBRUARY 17, 1993) TO SEPTEMBER 30, 2001

<CAPTION>
                                                                                  From
                                                                               Inception
                                                                              (February 17,
                                                    Nine Months Ended 09/30     1993) to
                                                   ------------------------   September 30,
                                                      2001         2000           2001
                                                   -----------  -----------   -------------
<S>                                                <C>          <C>            <C>
Cash Flows From Operating Activities
   Net Loss                                        $  (334,713) $  (638,058)   $ (4,347,334)
   Adjustments to Reconcile Net Loss
      to Net Cash Used In Operating Activities
         Common Stock Issued For Services Rendered     213,500       21,200         284,700
         Compensation Cost-Stock Options                     0        6,000           6,000
         Depreciation and Amortization                       0        3,717          10,778
         Write Off of Patents                                0            0       2,100,007
         Write Off of Organizational Costs                   0            0         102,500
         Write Off Inventory                                 0            0          40,395
   Changes in Assets and Liabilities
         Increase (Decrease) in Accrued Interest          (680)       4,955          20,430
         Increase (Decrease) in Accounts Payable        28,281      177,132         299,069
                                                   -----------  -----------   -------------
   Total Adjustments                                   241,101      213,004       2,863,879
                                                   -----------  -----------   -------------
Net Cash Used In Operating Activities                  (93,612)    (425,054)     (1,483,455)

Cash Flows From Investing Activities
   Loans from Shareholder                               69,000         -            256,005
                                                   -----------  -----------   -------------
Net Cash Provided by Investing Activities               69,000         -            256,005

Cash Flows From Financing Activities
   Proceeds From the Sale of Common Stock                    0      195,000       1,095,000
   Offering Costs                                            0            0        (120,600)
   Borrowings Under Notes Payable                            0      230,000         250,000
                                                   -----------  -----------   -------------
Net Cash Provided By Financing Activities                    0      425,000       1,224,400
                                                   -----------  -----------   -------------

Increase (Decrease) in Cash and Cash Equivalents       (24,612)         (54)         (3,050)

Cash and Cash Equivalents, Beginning of Period          24,623        4,508           3,061
                                                   -----------  -----------   -------------

Cash and Cash Equivalents, End of Period           $        11  $     4,454   $          11
                                                   ===========  ===========   =============

Supplemental Information:
Cash paid for:
   Interest                                        $         0  $         0   $           0
                                                   ===========  ===========   =============
   Income taxes                                    $         0  $         0   $           0
                                                   ===========  ===========   =============

Supplemental Noncash Investing
and Financing Activities:
   Common Stock Issued For Services Rendered       $   213,500  $    21,200   $     284,700
                                                   ===========  ===========   =============
   Compensation Cost                               $         0  $     6,000   $       6,000
                                                   ===========  ===========   =============
   Conversion of Debt to Equity                    $   249,619  $         0   $   1,499,619
                                                   ===========  ===========   =============
   Assets Acquired for Common Stock                $         0  $         0   $   1,020,465
                                                   ===========  ===========   =============
   Common Stock Issued as Dividends-in-kind        $         0  $         0   $   2,008,096
                                                   ===========  ===========   =============
   Conversion of Accounts Payable to Equity        $    31,500  $         0   $     206,000
                                                   ===========  ===========   =============

<FN>
                 See condensed notes to financial statements.
</TABLE>
                                    -  5 -
===============================================================================
<PAGE>
                              HEALTHBRIDGE, INC.

                     NOTES TO INTERIM FINANCIAL STATEMENTS
                              SEPTEMBER 30, 2001


NOTE 1.  STATEMENT OF INFORMATION FURNISHED

The accompanying unaudited interim financial statements have been prepared
in accordance with Form 10QSB instructions and in the opinion of management
contains all adjustments (consisting of only normal recurring adjustments)
necessary to present fairly the financial position as of September 30, 2001,
and the results of operations and cash flows for the three and nine months
ended September 30, 2001 and 2000.  These results have been determined on the
basis of generally accepted accounting principles and practices and applied
consistently with those used in the preparation of the Company's 2000 Annual
Report on Form 10-KSB.

Certain information and footnote disclosure normally included in the financial
statements presented in accordance with generally accepted accounting
principles have been condensed or omitted.  It is suggested that the
accompanying financial statements be read in conjunction with the accompanying
audited financial statements and notes thereto incorporated by reference in the
Company's 2000 Annual Report on Form 10-SB.


NOTE 2.  PRESENTATION

Certain accounts have been reclassified to confirm to the current period's
presentation.  These changes had no effect on previously reported results of
operations or total stockholders' equity.


NOTE 3.  GOING CONCERN, FINANCIAL RESULTS AND LIQUIDITY

To date, we have not been profitable. We face all the risks common to companies
in their early stages of development, including undercapitalization and
uncertainty of funding sources, high initial expenditure levels and uncertain
revenue streams, an unproven business model, and difficulties in managing
growth. Our recurring losses raise substantial doubt about our ability to
continue as a going concern. Our financial statements do not reflect any
adjustments that might result from the outcome of this uncertainty. The Company
expects to incur losses as it expands its business and will require additional
funding during the next twelve months. The satisfaction of our cash
requirements hereafter will depend in large part on our ability to successfully
raise capital from external sources to fund operations.  As a result, we expect
to aggressively pursue additional sources of funds, the form of which will vary
depending upon prevailing market and other conditions and may include a sale
transaction or the issuance of equity securities.

The Company is exploring the possibility of selling, merging or purchasing
assets from another Company. Although the Company has not entered into any
binding agreement to effect such a transaction, the board of directors of the
Company does consider such offers and would consider all of the terms of any
such offer as part of its fiduciary duty to determine whether any such
transaction is in the best interest of the Company's stockholders. If our board
of directors does determine that a sale, merger or purchase of assets from
another Company is in the best interests of the Company's stockholders,
our board of directors may determine to pursue such a transaction and the
consideration to be paid in connection with such transaction would be used to
expand our business and fund future operations. We cannot assure you that we
will be able to raise funds through a sale or equity transaction, or if such
funding is available, that it will be on favorable terms.  Our common stock is
currently traded on the over-the-counter market on an electronic bulletin board
established for securities that do not meet Nasdaq listing requirements or in
what are commonly referred to as the "pink sheets."

<TABLE>
NOTE 4 - EARNINGS PER SHARE

Basic earnings or loss per share is based on the weighted average number
of shares outstanding during the period of the financial statements.
Diluted earnings or loss per share are based on the weighted average number
of common shares outstanding and dilutive common stock equivalents.
All per share and per share information are adjusted retroactively to reflect
stock splits and changes in par value, when applicable.  All earnings or loss
per share amounts in the financial statements are basic earnings or loss per
share.  The computation of basic loss per share is as follows:
<CAPTION>
                                       Three Months Ended 09/30   Nine Months Ended 09/30
                                       ------------------------  ------------------------
                                          2001         2000         2001         2000
                                       -----------  -----------  -----------  -----------
<S>                                    <C>          <C>           <C>         <C>

Numerator-Net Loss Available
   to Common Stockholders              $  (178,768) $  (112,362) $  (334,713) $  (638,058)
                                       ===========  ===========  ===========  ===========
Denominator-Weighted Average Number
   of Common Shares Outstanding         14,753,563   12,650,618   13,896,800   12,198,396
                                       ===========  ===========  ===========  ===========

Basic Loss Per Common Share            $    (0.01)  $    (0.02)  $    (0.02)  $    (0.05)
                                       ===========  ===========  ===========  ===========
</TABLE>
                                    -  6 -
===============================================================================
<PAGE>

Item 2.  Management's Discussion and Analysis of Financial Condition
         and Results of Operations.
--------------------------------------------------------------------

When used in this discussion, the words "believes", "anticipates", "expects",
and similar expressions are intended to identify forward-looking statements.
Such statements are subject to certain risks and uncertainties, which could
cause actual results to differ materially from those projected. Readers are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. Healthbridge, Inc. (Healthbridge)
undertakes no obligation to republish revised forward-looking statements to
reflect events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events. Readers are also urged to carefully review
and consider the various disclosures made by Healthbridge which attempt to
advise interested parties of the factors which affect the Healthbridge's
business, in this report, as well as the Healthbridge's periodic reports on
Forms 10-KSB, 10QSB and 8-K filed with the Securities and Exchange Commission.

PLAN OF OPERATION.  During the development stage of the Company's "Redloc II"
Waste Disposal System, Healthbridge operated a Beta-Test Site at a Dallas,
Texas hospital. This site was suspended in June 2000 after a very successful
4-year test operation. During that time, Healthbridge was able to identify
shortcomings which needed modification and enhancement of the Systems'
efficiency prior to full-scale marketing. The Company's management is assessing
the viability of making the required changes and enhancement to the Redloc II
System under the current market conditions. Healthbridge does not rule out not
to proceed with further development and additional requirements of the EPA make
incineration prohibitively expensive and raise demand for alternative systems,
such as the Company's Redloc II System.  In the meantime, management continues
to pursue other business opportunities.

On July 10, 2001, Healthbridge announced it entered into a Letter of Intent
with a German company for the acquisiton of all the intellectual property,
the corresponding patents and know-how relating to a similar technology for
disinfecting and sterilizing of infectious waste material. The Letter of Intent
provides for the issuance of shares of the Company of a value of $800,000 and a
cash payment of $200,000, subject to the execution of a definitive formal
agreement and the satisfactory due.

FINANCING.  At September 30, 2001, the Company owed approximately $340,000 in
accounts payable.  During 2001, Healthbridge received funds from a shareholder
to support its working capital needs and Healthbridge converted approximately
$281,000 of existing debt to equity.  Healthbridge anticipates satisfying its
cash requirements from advances by shareholder/management and through the
issuance of common stock in payment for debt or services rendered.
The satisfaction of our cash requirements hereafter will depend in large part
on Healthbridge's ability to successfully raise capital from external sources
to fund operations or to successfully merge with another Company.  As a result,
Healthbridge expects to aggressively pursue additional sources of funds,
the form of which will vary depending upon prevailing market and other
conditions and may include a sale transaction or the issuance of equity
securities.

RECENT ACCOUNTING PRONOUNCEMENTS

In June 2001, the Financial Accounting Standards Board ("FASB") issued
SFAS No. 141 "Business Combinations". SFAS No. 141 requires that all business
combinations be accounted for under the purchase method of accounting.
SFAS No. 141 also changes the criteria for the separate recognition of
intangible assets acquired in a business combination. SFAS No. 141 is effective
for all business combinations initiated after June 30, 2001. This statement is
not expected to significantly affect the financial statements.

In June 2001, the FASB issued SFAS No. 142, "Goodwill and Other Intangible
Assets". SFAS No. 142 addresses accounting and reporting for intangible assets
acquired, except for those acquired in a business combination. SFAS No. 142
presumes that goodwill and certain intangible assets have indefinite useful
lives. Accordingly, goodwill and certain intangibles will not be amortized
but rather will be tested at least annually for impairment. SFAS No. 142 also
addresses accounting and reporting for goodwill and other intangible assets
subsequent to their acquisition. SFAS No. 142 is effective for fiscal years
beginning after December 15, 2001. This statement does not significantly affect
the financial statements.

In June 2001, the FASB issued SFAS No. 143, "Accounting for Asset Retirement
Obligations". SFAS No. 143 addresses financial accounting and reporting for
obligations associated with the retirement of tangible long-lived assets and
the associated asset retirement costs. SFAS No. 143 is effective for financial
statements issued for fiscal years beginning after June 15, 2002.
This statement is not expected to have a significant effect on the financial
statements.

In August 2001, tbe FASB issued SFAS No. 144, "Accounting for the Impairment or
Disposal of Long-Lived Assets" which supersedes SFAS No. 121. This statement
addresses financial accounting and reporting for the impairment or disposal of
long-lived assets. SFAS No. 144 is effective for financial statements issued
for fiscal years beginning after December 15, 2001, and interim periods within
those fiscal years. This statement is not expected to have a significant effect
on the financial statements.

                                    -  7 -
===============================================================================
<PAGE>

PART II
-------
Item 1.  Legal Proceedings.
---------------------------

         None.

Item 2.  Changes in Securities.
-------------------------------

         Securities issued for the nine months ended September 30, 2001 were
as follows:

         (1)  March 5, 2001-30,000 shares of common stock issued for exercise
              of options at $0.10 per share, or $3,000.

         (2)  April 25, 2001-15,000 shares of common stock issued for services
              rendered at $0.10 per share, or $1,500.

         (3)  May 2, 2001-400,000 shares of common stock issued for services
              rendered at $0.17 per share, or $68,000.

         (4)  June 15, 2001-346,535 shares of common stock issued for
              conversion of debt to equity at $0.30 per share, or $103,961.

         (5)  June 15, 2001-295,526 shares of common stock issued for
              conversion of debt to equity at $0.30 per share, or $88,658.

         (6)  June 15, 2001-190,000 shares of common stock issued for
              conversion of debt to equity at $0.30 per share, or $57,000.

         (7)  June 28, 2001-75,000 shares of common stock issued for services
              rendered at $0.40 per share, or $30,000.

         (8)  September 14, 2001-950,000 shares of common stock issued for
              services rendered at $0.15 per share, or $142,500.

Item 3.  Defaults Upon Senior Securities.
-----------------------------------------

         None.

Item 4.  Submission of Matters to Vote of Security Holders.
-----------------------------------------------------------

         None.

Item 5.  Other Information.
---------------------------

         None.

Item 6.  Exhibits and Reports on Form 8-K.
-----------------------------------------

         None.

                                    -  8 -
===============================================================================
<PAGE>


                                  SIGNATURES


In accordance with Section 13 or 15(d) of the Exchange Act, the Registrant
caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.


Healthbridge, Inc.                     By: /s/ Nora Coccaro
                                           --------------------------
                                               Nora Coccaro President


Dated:  November 13, 2001

                                    -  9 -
===============================================================================
<PAGE>